Placeholder Banner

BIO Submits Comments on WHO Guideline: Nonclinical and Clinical Evaluation of Monoclonal Antibodies and Related Biological Products Intended for the Prevention or Treatment of Human Infectious Diseases

October 28, 2022

On October 28th, BIO submitted comments to the World Health Organization on its new draft guideline containing regulatory considerations and requirements for the marketing authorization of monoclonal antibodies (mAbs) and related products based on an immunoglobulin framework. In the comments submitted, BIO stated strong support for WHO’s mission to ensure the equitable and widespread availability of safe, effective, and quality health products. With this objective in mind, BIO also provided several overarching recommendations. First, BIO encouraged further incorporation of the 3Rs principles (replacement, reduction, and refinement of animal use) throughout the guideline. While nonclinical in vivo studies continue to provide critical information to sponsors and regulators on the safety and efficacy of products, BIO urged WHO to reconsider when such studies are truly necessary in the context of this guideline as in vitro technologies and computational models (e.g., physiological based pharmacokinetic models) can be leveraged to inform nonclinical assessments. BIO also suggested that WHO refine the guideline broadly to ensure consistency with existing international guidelines, such as the ICH S6 Guideline. Furthermore, BIO stated that the acknowledgement and incorporation of current regional guidances where possible and applicable, especially those that have been issued since the COVID-19 pandemic, would be beneficial.

Download Full Comments Below
BIO Comments on WHO MAbs Guideline
Discover More
On October 28th, BIO submitted comments on the ICH E11A Pediatric Extrapolation Guideline as published by the Food & Drug Administration (FDA). In the comments submitted, BIO voiced appreciation for the guideline’s clear explanation for how…
On November 1st, BIO submitted comments in response to the Food & Drug Administration’s (FDA) recent Pharmaceutical Science and Clinical Pharmacology Advisory Committee meeting. The meeting was primarily focused on two topics: the future of the…
On Friday, September 23rd, BIO submitted comments in response to a new draft guidance describing FDA’s perspective on its use of remote regulatory assessments (RRAs). In particular, the draft guidance responded to frequently asked questions on what…